Activity of compound 506U78 in patients with refractory T-cell malignancies: A POG/CCG intergroup phase 2 study.

被引：0
|
作者：
Berg, SL
Blaney, SM
Bernstein, M
Kurtzberg, J
Devidas, M
Lampkin, T
Murgo, AJ
Harris, MB
机构：
[1] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA
[2] Hop St Justine, Montreal, PQ H3T 1C5, Canada
[3] Duke Univ, Med Ctr, Durham, NC 27706 USA
[4] Childrens Oncol Grp, Gainesville, FL USA
[5] GlaxoSmithKline, Collegeville, PA USA
[6] NCI, Invest Drug Branch, Canc Therapy Evaluat Program, Rockville, MD USA
[7] Hackensack Univ, Tomorrow Childrens Inst, Med Ctr, Hackensack, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
792
引用
收藏
页码：226A / 226A
页数：1
相关论文
共 50 条
  • [21] A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL)
    Goh, Yeow-Tee
    Hwang, William Y. K.
    Diong, Colin Phipps
    Hsien, Yap Chun
    Tay, Kevin
    Lim, Soon Thye
    Lee, Yuh Shan
    Ng, Soo Chin
    Fadilah, S.
    Kim, Won Seog
    Tan, Daryl
    BLOOD, 2014, 124 (21)
  • [22] Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies
    Kadia, Tapan M.
    Kantarjian, Hagop
    Alatrash, Gheath
    Sergeeva, Anna
    He, Hong
    St. John, Lisa
    Koppikar, Priya
    Kerros, Celine
    Clise-Dwyer, Karen
    Ruissard, Kathryn
    Maiti, Abhishek
    DiNardo, Courtney D.
    Jabbour, Elias
    Verstovsek, Srdan
    Pemmaraju, Naveen
    Jain, Nitin
    Issa, Ghayas C.
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    Shastri, Aditi
    Couriel, Daniel R.
    Pinsoy, Maria Rhona
    Parshottham, Sapna
    Champlin, Richard E.
    Cortes, Jorge
    Molldrem, Jeffrey J.
    BLOOD, 2023, 142
  • [23] Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies
    Hill, LaQuisa C.
    Rouce, Rayne H.
    Smith, Tyler S.
    Yang, Lina
    Srinivasan, Madhuwanti
    Zhang, Huimin
    Perconti, Silvana
    Mehta, Birju
    Dakhova, Olga
    Randall, Josalind
    Grilley, Bambi J.
    Heslop, Helen E.
    Brenner, Malcolm K.
    Mamonkin, Maksim
    BLOOD, 2019, 134
  • [24] Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Maeda, Yoshinobu
    Nakane, Takahiko
    Shimoyama, Tatsu
    Nakazato, Tomonori
    Sakai, Rika
    Ishikawa, Takayuki
    Izutsu, Koji
    Ueda, Ryuzo
    Tobinai, Kensei
    CANCER SCIENCE, 2017, 108 (10): : 2061 - 2068
  • [25] A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma
    Ishitsuka, Kenji
    Utsunomiya, Atae
    Katsuya, Hiroo
    Takeuchi, Shogo
    Takatsuka, Yoshifusa
    Hidaka, Michihiro
    Sakai, Tatsunori
    Yoshimitsu, Makoto
    Ishida, Takashi
    Tamura, Kazuo
    CANCER SCIENCE, 2015, 106 (09): : 1219 - 1223
  • [26] Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study
    Nicolay, Jan P.
    Melchers, Susanne
    Albrecht, Jana D.
    Assaf, Chalid
    Dippel, Edgar
    Stadler, Rudolf
    Wehkamp, Ulrike
    Wobser, Marion
    Zhao, Jing
    Burghaus, Ina
    Schneider, Sven
    Guelow, Karsten
    Goerdt, Sergij
    Schuerch, Christian M.
    Utikal, Jochen S.
    Krammer, Peter H.
    BLOOD, 2023, 142 (09) : 794 - 805
  • [27] A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies
    Collins, Graham P.
    Clevenger, Tracy N.
    Burke, Kathleen A.
    Yang, Buyue
    MacDonald, Alex
    Cunningham, David
    Fox, Christopher P.
    Goy, Andre
    Gribben, John
    Nowakowski, Grzegorz S.
    Roschewski, Mark
    Vose, Julie M.
    Vallurupalli, Anusha
    Cheung, Jean
    Raymond, Amelia
    Nuttall, Barrett
    Stetson, Dan
    Dougherty, Brian A.
    Schalkwijk, Stein
    Carnevalli, Larissa S.
    Willis, Brandon
    Tao, Lin
    Harrington, Elizabeth A.
    Hamdy, Ahmed
    Izumi, Raquel
    Pease, J. Elizabeth
    Frigault, Melanie M.
    Flinn, Ian
    LEUKEMIA & LYMPHOMA, 2021, 62 (11) : 2625 - 2636
  • [28] Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib
    Shadman, Mazyar
    Sharman, Jeff P.
    Levy, Moshe Y.
    Misleh, Jamal
    Zafar, Syed F.
    Freeman, Benjamin B.
    Burke, John M.
    Cultrera, Jennifer L.
    Yimer, Habte A.
    Chen, Dih-Yih
    Zhang, Xiaoping
    Cohen, Aileen
    Ro, Sunhee
    Huang, Jane
    Flinn, Ian W.
    BLOOD, 2020, 136
  • [29] Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study
    Dai Maruyama
    Kensei Tobinai
    Michinori Ogura
    Toshiki Uchida
    Kiyohiko Hatake
    Masafumi Taniwaki
    Kiyoshi Ando
    Kunihiro Tsukasaki
    Takashi Ishida
    Naoki Kobayashi
    Kenichi Ishizawa
    Yoichi Tatsumi
    Koji Kato
    Toru Kiguchi
    Takayuki Ikezoe
    Eric Laille
    Tokihiro Ro
    Hiromi Tamakoshi
    Sanae Sakurai
    Tomoko Ohtsu
    International Journal of Hematology, 2017, 106 : 655 - 665
  • [30] A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas
    Boonstra, Philip S.
    Polk, Avery
    Brown, Noah
    Hristov, Alexandra C.
    Bailey, Nathanael G.
    Kaminski, Mark S.
    Phillips, Tycel
    Devata, Sumana
    Mayer, Tera
    Wilcox, Ryan A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (12) : 1287 - 1294
12345